Allogene Therapeutics is a biotechnology firm pioneering off-the-shelf CAR-T therapies using donor-derived cells. Unlike personalized treatments, their allogeneic approach enables immediate, scalable cancer care, reducing wait times for patients with blood cancers. By engineering healthy donor T-cells, they aim to make immunotherapy more accessible, benefiting those with aggressive or relapsed malignancies who need rapid, reliable treatment options.
Get alerts when this topic surges in newsletters. Free to start.
Sign up freeExplore more trends:Trending Topics ·AI Trends ·Business Trends ·Finance Trends ·Technology Trends